A detailed history of American International Group, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 65,397 shares of LCTX stock, worth $60,819. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,397
Previous 65,959 0.85%
Holding current value
$60,819
Previous $71,000 35.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.86 - $1.48 $483 - $831
-562 Reduced 0.85%
65,397 $96,000
Q4 2023

Feb 13, 2024

BUY
$0.91 - $1.35 $1,415 - $2,099
1,555 Added 2.41%
65,959 $71,000
Q3 2023

Nov 13, 2023

BUY
$1.16 - $1.53 $2,656 - $3,503
2,290 Added 3.69%
64,404 $75,000
Q2 2023

Aug 04, 2023

BUY
$1.26 - $1.53 $78,263 - $95,034
62,114 New
62,114 $87,000
Q2 2022

Aug 12, 2022

SELL
$1.12 - $1.61 $69,736 - $100,246
-62,265 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$1.21 - $2.48 $5,302 - $10,867
-4,382 Reduced 6.57%
62,265 $96,000
Q4 2021

Feb 11, 2022

SELL
$1.84 - $2.68 $3,670 - $5,346
-1,995 Reduced 2.91%
66,647 $163,000
Q3 2021

Nov 12, 2021

BUY
$2.26 - $2.86 $1,568 - $1,984
694 Added 1.02%
68,642 $173,000
Q2 2021

Aug 13, 2021

BUY
$2.17 - $3.0 $147,447 - $203,844
67,948 New
67,948 $194,000
Q2 2020

Aug 12, 2020

SELL
$0.71 - $1.18 $45,455 - $75,545
-64,022 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$0.6 - $1.58 $2,218 - $5,842
-3,698 Reduced 5.46%
64,022 $53,000
Q4 2019

Feb 05, 2020

SELL
$0.54 - $1.01 $307 - $575
-570 Reduced 0.83%
67,720 $60,000
Q3 2019

Nov 08, 2019

BUY
$0.85 - $1.24 $58,046 - $84,679
68,290 New
68,290 $67,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $158M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.